Biomarker discovery and validation: Technologies and integrative approaches

Trends in Biotechnology

Volumn 22, Issue 8, 2004, Pages 411-416

  Ilyin, Sergey E ^a   Belkowski, Stanley M ^a   Plata Salamán, Carlos R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOMARKERS; DIAGNOSIS; MONITORING; PHYSIOLOGY;

DISEASE PROGRESSION; PHARMCODYNAMICS;

BIOTECHNOLOGY;

BIOLOGICAL MARKER; FLUOXETINE; NORTRIPTYLINE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOMATION; BIOINFORMATICS; BIOTECHNOLOGY; CARCINOGENESIS; CLINICAL TRIAL; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; DNA SEQUENCE; DNA TEMPLATE; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENOMICS; HEALTH ECONOMICS; HUMAN; INFORMATION PROCESSING; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RELAPSE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOXICOLOGY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DATA COLLECTION; GENOMICS; HUMANS; PROTEOMICS;

EID: 3342964033     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2004.06.005     Document Type: Review

References (26)

1. Rudin M., Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;123-131
2. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
3. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;566-580
4. Petricoin, E.F. and Liotta, L.A. (2002) Proteomic analysis at the bedside: early detection of cancer. Trends Biotechnol. 20 (12 Suppl), S30-S34.
5. Ilyin S.E., et al. Emerging paradigms in applied bioinformatics. BioSilico. 3:2003;86-88
6. Welsh J.B., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1176-1181
7. Staal F.J., et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia. 17:2003;1324-1332
8. Xin W., et al. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 162:2003;255-261
9. Joyce P.R., et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 6:2003;339-346
10. Robosky L.C., et al. In vivo toxicity screening programs using metabonomics. Comb. Chem. High Throughput Screen. 5:2002;651-662
11. Martinez-Cruz L.A., et al. GARBAN: genomic analysis and rapid biological annotation of cDNA microarray and proteomic data. Bioinformatics. 19:2003;2158-2160
12. Darrow A.L., et al. Virus-based expression systems facilitate rapid target in vivo functionality validation and high-throughput screening. J. Biomol. Screen. 8:2003;65-71
13. Chen G., et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics. 1:2002;304-313
14. Hanash S.M., et al. Integrating cancer genomics and proteomics in the post-genome era. Proteomics. 2:2002;69-75
15. Orntoft T.F., et al. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol. Cell. Proteomics. 1:2002;37-45
16. Nishizuka S., et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63:2003;5243-5250
17. Huber M., et al. Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. Mol. Cell. Proteomics. 3:2003;43-55
18. Gygi S.P., et al. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19:1999;1720-1730
19. Lueking A., et al. A non-redundant human protein chip for antibody screening and serum profiling. Mol. Cell. Proteomics. 2:2003;1342-1349
20. Schweitzer B., et al. Microarrays to characterize protein interactions on a whole-proteome scale. Proteomics. 3:2003;2190-2199
21. He M., Taussig M.J. DiscernArray technology: a cell-free method for the generation of protein arrays from PCR DNA. J. Immunol. Methods. 274:2003;265-270
22. Qu Y., et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48:2002;1835-1843
23. Pinhasov A., et al. Gene expression analysis for high throughput screening applications. Comb. Chem. High Throughput Screen. 7:2004;133-140
24. Bernal A., et al. Emerging opportunities in functional informatics. PharmaGenomics. 9:2003;38-44
25. Xin H., et al. High throughput siRNA-based functional target validation. J. Biomol. Screen. 9:2004;286-293
26. Belkowski S., Ilyin S.E. Integrative functional informatics. Drug Discov. Dev. 10:2003;77-78